117 related articles for article (PubMed ID: 32122993)
1. GITR Agonism Triggers Antitumor Immune Responses through IL21-Expressing Follicular Helper T Cells.
Koh CH; Kim IK; Shin KS; Jeon I; Song B; Lee JM; Bae EA; Seo H; Kang TS; Kim BS; Chung Y; Kang CY
Cancer Immunol Res; 2020 May; 8(5):698-709. PubMed ID: 32122993
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells.
Kim IK; Kim BS; Koh CH; Seok JW; Park JS; Shin KS; Bae EA; Lee GE; Jeon H; Cho J; Jung Y; Han D; Kwon BS; Lee HY; Chung Y; Kang CY
Nat Med; 2015 Sep; 21(9):1010-7. PubMed ID: 26280119
[TBL] [Abstract][Full Text] [Related]
3. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
[TBL] [Abstract][Full Text] [Related]
4. GITR shapes humoral immunity by controlling the balance between follicular T helper cells and regulatory T follicular cells.
Oja AE; Brasser G; Slot E; van Lier RAW; Pascutti MF; Nolte MA
Immunol Lett; 2020 Jun; 222():73-79. PubMed ID: 32259529
[TBL] [Abstract][Full Text] [Related]
5. GITR Agonism Enhances Cellular Metabolism to Support CD8
Sabharwal SS; Rosen DB; Grein J; Tedesco D; Joyce-Shaikh B; Ueda R; Semana M; Bauer M; Bang K; Stevenson C; Cua DJ; Zúñiga LA
Cancer Immunol Res; 2018 Oct; 6(10):1199-1211. PubMed ID: 30154083
[TBL] [Abstract][Full Text] [Related]
6. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia.
Ahearne MJ; Willimott S; Piñon L; Kennedy DB; Miall F; Dyer MJ; Wagner SD
Br J Haematol; 2013 Aug; 162(3):360-70. PubMed ID: 23710828
[TBL] [Abstract][Full Text] [Related]
8. Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells.
Sukumar S; Wilson DC; Yu Y; Wong J; Naravula S; Ermakov G; Riener R; Bhagwat B; Necheva AS; Grein J; Churakova T; Mangadu R; Georgiev P; Manfra D; Pinheiro EM; Sriram V; Bailey WJ; Herzyk D; McClanahan TK; Willingham A; Beebe AM; Sadekova S
Cancer Res; 2017 Aug; 77(16):4378-4388. PubMed ID: 28611044
[TBL] [Abstract][Full Text] [Related]
9. Interleukin‑21 promotes the development of ulcerative colitis and regulates the proliferation and secretion of follicular T helper cells in the colitides microenvironment.
Yu J; He S; Liu P; Hu Y; Wang L; Wang X; Han Y; Zhu X
Mol Med Rep; 2015 Feb; 11(2):1049-56. PubMed ID: 25371082
[TBL] [Abstract][Full Text] [Related]
10. Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma.
Scirka B; Szurek E; Pietrzak M; Rempala G; Kisielow P; Ignatowicz L; Miazek A
Arch Immunol Ther Exp (Warsz); 2017 Dec; 65(6):553-564. PubMed ID: 28638937
[TBL] [Abstract][Full Text] [Related]
11. Critical role of Interleukin 21 and T follicular helper cells in hypertension and vascular dysfunction.
Dale BL; Pandey AK; Chen Y; Smart CD; Laroumanie F; Ao M; Xiao L; Dikalova AE; Dikalov SI; Elijovich F; Foss JD; Barbaro NR; Van Beusecum JP; Deger SM; Alsouqi A; Itani HA; Norlander AE; Alexander MR; Zhao S; Ikizler TA; Algood HMS; Madhur MS
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013256
[TBL] [Abstract][Full Text] [Related]
12. The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice.
Brunn ND; Mauze S; Gu D; Wiswell D; Ueda R; Hodges D; Beebe AM; Zhang S; Escandón E
J Pharmacol Exp Ther; 2016 Mar; 356(3):574-86. PubMed ID: 26669426
[TBL] [Abstract][Full Text] [Related]
13. Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.
Murphy JT; Burey AP; Beebe AM; Gu D; Presta LG; Merghoub T; Wolchok JD
Blood; 2014 Apr; 123(14):2172-80. PubMed ID: 24558202
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.
Ramirez-Montagut T; Chow A; Hirschhorn-Cymerman D; Terwey TH; Kochman AA; Lu S; Miles RC; Sakaguchi S; Houghton AN; van den Brink MR
J Immunol; 2006 Jun; 176(11):6434-42. PubMed ID: 16709800
[TBL] [Abstract][Full Text] [Related]
15. Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma.
Pan C; Wu Q; Wang S; Mei Z; Zhang L; Gao X; Qian J; Xu Z; Zhang K; Su R; Guo D; Zhou L; Zheng S
Oncoimmunology; 2022; 11(1):2073010. PubMed ID: 35558158
[TBL] [Abstract][Full Text] [Related]
16. Blockade of Glucocorticoid-Induced Tumor Necrosis Factor-Receptor-Related Protein Signaling Ameliorates Murine Collagen-Induced Arthritis by Modulating Follicular Helper T Cells.
Ma J; Feng D; Wei Y; Tian J; Tang X; Rui K; Lu L; Xu H; Wang S
Am J Pathol; 2016 Jun; 186(6):1559-67. PubMed ID: 27106763
[TBL] [Abstract][Full Text] [Related]
17. Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors.
Zhou P; L'italien L; Hodges D; Schebye XM
J Immunol; 2007 Dec; 179(11):7365-75. PubMed ID: 18025180
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
Yu N; Fu S; Xu Z; Liu Y; Hao J; Zhang A; Wang B
Int J Cancer; 2016 Jan; 138(2):451-62. PubMed ID: 26239999
[TBL] [Abstract][Full Text] [Related]
19. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
20. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.
Schaer DA; Budhu S; Liu C; Bryson C; Malandro N; Cohen A; Zhong H; Yang X; Houghton AN; Merghoub T; Wolchok JD
Cancer Immunol Res; 2013 Nov; 1(5):320-31. PubMed ID: 24416730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]